Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heartache For Novartis As Serelaxin Failure Ups Pressure On Entresto

Executive Summary

Novartis's latest Phase III study of serelaxin has failed, deleting a significant chunk of forecasted revenue that analysts had attributed to the heart failure drug candidate.

Advertisement

Related Content

The Year's Clinical Trials In Review: Big Misses In 2017
Novartis Claims New Drugs, Pipeline Will Fuel Growth, Not M&A
1Q Pharma Results Preview: Biogen, Novartis, Lilly, Amgen, GSK, AstraZeneca, BMS, AbbVie, Roche, Bayer, Sanofi
Keeping Track: US FDA Clears Three Novel Agents Over Three Days – Bavencio, Symproic And Xadago
Can Slow Selling Heart Drug Entresto Perk Up In 2017? Novartis Hopes So
Novartis Chief: Good Things Come To Those Who Wait
FDA reviewers advise no go for Novartis' serelaxin

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098444

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel